Literature DB >> 25754491

8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.

Toshiaki Sakamoto1, Yuichi Koga1, Masataka Hikota1, Kenji Matsuki1, Hideki Mochida2, Kohei Kikkawa2, Kotomi Fujishige3, Jun Kotera3, Kenji Omori4, Hiroshi Morimoto5, Koichiro Yamada1.   

Abstract

A novel series of highly selective phosphodiesterase 5 (PDE5) inhibitors was found. 8H-Pyrido[2,3-d]pyrimidin-7-one derivatives bearing an (S)-2-(hydroxymethyl)pyrrolidin-1-yl group at the 2-position and a 3-chloro-4-methoxybenzyl group at the 8-position exhibited potent PDE5 inhibitory activities and high PDE5 selectivity over PDE6. Among the synthesized compounds, the 5-methyl analogue (5b) showed the most potent relaxant effect on isolated rabbit corpus cavernosum with an EC30 value of 0.85 nM.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Erectile dysfunction; PDE5; PDE6

Mesh:

Substances:

Year:  2015        PMID: 25754491     DOI: 10.1016/j.bmcl.2015.02.041

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.

Authors:  Gülru Kayık; Nurcan Ş Tüzün; Serdar Durdagi
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 2.  Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications.

Authors:  Guillem Jubete; Raimon Puig de la Bellacasa; Roger Estrada-Tejedor; Jordi Teixidó; José I Borrell
Journal:  Molecules       Date:  2019-11-16       Impact factor: 4.411

3.  LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application.

Authors:  Ahmed K Kammoun; Alaa Khedr; Osama A A Ahmed
Journal:  RSC Adv       Date:  2020-03-04       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.